Delivery Order SPE2DB22D1017-SPE2DB25FE7HY

Award Date 10/16/24
Potential Completion Date 11/6/24
Potential Value $5.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,007.90 firm fixed-price delivery order is for the supply of 4567752226 TASIGNA 150 MG CAPSULE 28S. The contract has an ultimate completion date of April 21, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award, valued at $5,624.62, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TASIGNA 150 MG CAPSULE 28S, a medication, to support military healthcare programs. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running...
This federal contract award from the Defense Logistics Agency (DLA) is a delivery order with a firm fixed price of $11,638.02 and a completion date of March 25, 2025. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, to supply TASIGNA 150 MG CAPSULE 28S. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a...
This federal contract award, valued at $5,819.01, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of TASIGNA 150 MG CAPSULE 28S, a pharmaceutical product. The contract has an ultimate completion date of March 24, 2025 and is a Firm Fixed Price contract. The contract was not set aside for any specific business type. Amerisourcebergen Drug Corp...
This federal contract award, valued at $5,819.01, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type, and it covers the supply of TASIGNA 150 MG CAPSULE 28S, a pharmaceutical product, to support military healthcare programs. The contract has an ultimate completion date of January 28, 2025, and it is not designated as a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $12,015.80, is for the delivery of TASIGNA 150 MG CAPSULE 28S, a prescription medication. This is a firm fixed-price delivery order contract with an ultimate completion date of April 21, 2025. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen also...
This federal contract award, valued at $5,819.01, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TASIGNA 150 MG CAPSULE 28S, a pharmaceutical product, to support military healthcare programs. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award, valued at $5,819.01, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TASIGNA 150 MG CAPSULE 28S, a pharmaceutical product. The contract has an ultimate completion date of February 14, 2025 and is a Firm Fixed Price Delivery Order. There is no set-aside designation for this contract. AmerisourceBergen Drug Corp holds a...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract, valued at $5,819.01, is for the delivery of TASIGNA 200 MG CAPSULE 28S, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order with a period of performance through March 3, 2025. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp...
This federal contract award, valued at $11,638.02, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TASIGNA 200 MG CAPSULE 28S, a pharmaceutical product, and has a completion date of March 3, 2025. The contract is a Delivery Order with a Firm Fixed Price pricing type. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen...
  • SPE2DB22D1017
    Indefinite Delivery Contract
  • SPE2DB22D1017-SPE2DB25FE7HY
    Delivery Order

This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is for the delivery of TASIGNA 150 MG CAPSULE 28S, a pharmaceutical product, to support the Defense Logistics Agency (DLA) Troop Support Medical program. The contract, valued at $5,624.62, is a Firm Fixed Price Delivery Order with a completion date of November 6, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 1/15/25, 9:14 AM